All eyes on Moderna Q2 results with spotlight on COVID vaccine sales
Maddie Meyer

Moderna (NASDAQ:MRNA) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open.
The consensus EPS Estimate is $4.49 (-30.5% Y/Y) and the consensus Revenue Estimate is $3.95B (-9.2% Y/Y).
Over the last 2 years, MRNA has beaten EPS estimates 63% of the time and has beaten revenue estimates 75% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 3 upward revisions and 5 downward.
The company's stock rose +5.81% on May 4, the day it reported its Q1 results beating analysts' estimates. COVID-19 vaccine Spikevax made up $5.9B sales ahead of ~$5.1B in consensus.

A report in July noted that Pfizer, BioNTech and Moderna may post a sequential decline in COVID vaccine sales with their Q2 earnings reports. However, when Pfizer's Q2 results showed that COVID franchise continued to exceed forecasts.
The demand for Moderna' vaccine is still there as in July the company secured a $1.74B contract from the U.S. for its bivalent Omicron-adapted booster shots. The government is reportedly mulling plans to launch a booster campaign with the Omicron-adapted vaccines in September.
Moderna and EU agreed in June to push back delivery of COVID-19 vaccine to allow for member states to receive the booster shot later in 2022 or 2023.
While the U.S. FDA has stated that future COVID-19 booster shots should specifically include protection against the BA.4 and BA.5 Omicron subvariants, the European Medicines Agency noted that protection against original Omicron strain should be included in vaccine boosters.
Moderna's Omicron booster vaccine has shown response against subvariants in a trial.
Moderna was part of a groundbreaking "summit" in July that the White House convened as part of a broad initiative to develop next generation of COVID-19 immunizations.
The company's COVID vaccine also got approvals in Australia and Canada in younger kids. In June, Moderna noted that instances of a rare heart inflammation, myocarditis, among children after receiving their COVID-19 vaccine are extremely rare and is higher overall in patients that come down with COVID.
During Q2, Moderna announced plans to set up a mRNA vaccine manufacturing facility in U.K. The company also intends to invest ~â¬500M in Spain and open a laboratory to strengthen its vaccine production.
Product Pipeline: During Q2, Moderna began dosing of its Nipah virus vaccine mRNA-1215 in an early-stage study. The company also started dosing in a phase 3 trial of its seasonal influenza vaccine mRNA-1010. Moderna also said that it was investigating potential monkeypox vaccines at a pre-clinical stage. The company and a non-profit IAVI announced the launch of a first-in-Africa trial of an mRNA HIV vaccine.
Other news: In May, Moderna's CFO hire Jorge Gomez, who jumped ship from Dentsply Sirona, departed just 2 days into the job, as an internal probe at Dentsply came to light.